| scholarly article | Q13442814 |
| P2093 | author name string | G S Baxter | |
| N Day | |||
| J Carey | |||
| E S Ellis | |||
| R A Coleman | |||
| N S Tilford | |||
| R A Borman | |||
| D W Harmer | |||
| R L G Sheldrick | |||
| P2860 | cites work | Human colonic mucosa possesses a mixed population of 5-HT receptors | Q71692351 |
| Heterogeneity of 5-HT receptors mediating secretion in the human intestine | Q73423646 | ||
| Characterization of 5-HT receptors in rat proximal colon | Q74336179 | ||
| 5-HT1D and 5-HT2B receptors mediate contraction of smooth muscle in human small intestine | Q24310367 | ||
| Functional evidence for a 5‐HT2B receptor mediating contraction of longitudinal muscle in human small intestine | Q24317175 | ||
| RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist | Q24672108 | ||
| Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study | Q28379389 | ||
| Some quantitative uses of drug antagonists | Q29616831 | ||
| Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel | Q33701260 | ||
| Characterization of the contraction to 5-HT in the canine colon longitudinal muscle | Q35025759 | ||
| 5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle | Q35042832 | ||
| How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? | Q39196960 | ||
| The importance of 5-hydroxytryptamine receptors in the gut. | Q40649898 | ||
| Modulation of submucosal cholinergic neurons by 5-hydroxytryptamine and neuropeptides | Q41176207 | ||
| 5-Hydroxytryptamine and functional bowel disorders | Q41262792 | ||
| Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT. | Q41831320 | ||
| Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle | Q42368895 | ||
| 5-hydroxytryptamine release into human jejunum by cholera toxin | Q43226328 | ||
| Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle | Q43260817 | ||
| The role of the 5-HT4 receptor in Cl- secretion in human jejunal mucosa | Q45101902 | ||
| 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1p receptors on sensory CGRP neurons | Q45102002 | ||
| Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. | Q45115381 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1144-51 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro | |
| P478 | volume | 135 |
| Q36874372 | 5-HT receptors on interstitial cells of Cajal, smooth muscle and enteric nerves. |
| Q24309030 | A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties |
| Q57644802 | Benzylpiperazine-induced acute delirium in a patient with schizophrenia and an incidental temporal meningioma |
| Q34377189 | Colonic migrating motor complexes, high amplitude propagating contractions, neural reflexes and the importance of neuronal and mucosal serotonin |
| Q26851451 | Crohn's disease in women |
| Q24309173 | Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation |
| Q42221667 | Divergent changes to muscarinic and serotonergic signalling following colitis |
| Q37241590 | Effects of 5-HT2B, 5-HT3 and 5-HT4 receptor antagonists on gastrointestinal motor activity in dogs |
| Q57818362 | Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions |
| Q46613363 | Expression and function of 5-HT4 receptors in the mouse enteric nervous system |
| Q52716559 | Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines. |
| Q54989427 | Extensive projections of myenteric serotonergic neurons suggest they comprise the central processing unit in the colon |
| Q54114870 | Functions and Signaling Pathways of Amino Acids in Intestinal Inflammation. |
| Q39860291 | Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology |
| Q34342536 | Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors |
| Q34728081 | Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome |
| Q33863285 | Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease |
| Q36728938 | Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity |
| Q34143560 | Serotonin Receptors – From Molecular Biology to Clinical Applications |
| Q37132811 | Serotonin pharmacology in the gastrointestinal tract: a review |
| Q38178543 | Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome |
| Q33724343 | Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets |
| Q38055710 | Serotonin: from top to bottom. |
| Q45127969 | TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. |
| Q90094143 | Tegaserod for the Treatment of Irritable Bowel Syndrome |
| Q24671423 | The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo |
| Q33457198 | The effect of the menstrual cycle on inflammatory bowel disease: a prospective study |
| Q34770217 | The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity |
| Q35047051 | Treating irritable bowel syndrome: overview, perspective and future therapies |
Search more.